BAX and prostate carcinoma: The inhibition of the PI3K/AKT pathway, combined with the upregulation of the BAX/BCL2 ratio, collectively supports SSA’s pro-apoptotic and anti-tumor mechanisms, providing mechanistic evidence for its multi-targeted effects in prostate cancer treatment.